

REPORT TO THE LEGISLATURE  
Pursuant to P.A. 119 of 2023  
Article 2, Section 607  
MAT Clinics  
FY24 – 2<sup>nd</sup> Quarter

Sec. 607. (2) The department must submit quarterly reports on the status of establishment and operation of medication assisted treatment clinics. Reports shall include, but not be limited to, all of the following:

- (a) Site locations selected.
- (b) Staffing levels.
- (c) Expenditures on staffing and supplies, including oral and injectable medications.
- (d) Number of prisoners treated.
- (e) Number of prisoners requiring treatment but not yet receiving treatment.

Michigan Department of Corrections has 26 correctional facilities prescribing naltrexone and 10 of those correctional facilities are currently prescribing buprenorphine products for Medications for Assisted Treatment (MAT) for those diagnosed with an Opioid Use Disorder. MDOC has begun the initial steps to expand prescribing of buprenorphine products to three additional correctional facilities. Those three additional correctional facilities are expected to start prescribing over the next quarter. The information below is for the second quarter of FY24 and will be updated on the third quarter report as we have not received all the expenses for March due to pending invoices.

Site locations selected	Buprenorphine Sites	10
	Naltrexone Sites	26
	New MAT sites established	0
Staffing levels	Filled MAT Positions	13
	Vacant MAT Positions	4
Expenditures on staffing	State of Michigan:	\$34,651.47
	Temp:	\$175,833.84
	<b>TOTAL COST:</b>	<b><u>\$210,485.31</u></b>
Expenditures on supplies, including oral and injectable medications	*Sublocade:	\$1,700,505.25
	Suboxone:	\$31,077.00
	Naltrexone:	\$27,642.24
	<b>TOTAL COST:</b>	<b><u>\$1,759,224.49</u></b>
<i>(\$2.5 million dollars were used from the Opioid Settlement Fund to pay for Sublocade in Q1)</i>		
Number of prisoners treated	Number of inmates that have received at least 1 dose of MAT medication	
	<b>TOTAL:</b>	<b><u>1,374</u></b>
Number of prisoners requiring treatment but not yet receiving treatment	<b>TOTAL:</b>	<b><u>2,405</u></b>

Below is the updated expenses and information from quarter one as we received all invoices after the quarter one report was submitted.

Site locations selected	Buprenorphine Sites	10
	Naltrexone Sites	26
	New MAT sites established	0
Staffing levels	Filled MAT Positions	12
	Vacant MAT Positions	5
Expenditures on staffing	State of Michigan:	\$50,160.06
	Temp:	\$239,210.85
	<b>TOTAL COST:</b>	<b><u>\$289,370.91</u></b>
Expenditures on supplies, including oral and injectable medications	*Sublocade:	\$412,353.06
	Suboxone:	\$14,342.53
	Naltrexone:	\$19,238.82
	<b>TOTAL COST:</b>	<b><u>\$445,934.41</u></b>
<i>(\$2.5 million dollars were used from the Opioid Settlement Fund to pay for Sublocade in Q1)</i>		
Number of prisoners treated	Number of inmates that have received at least 1 dose of MAT medication	
	<b>TOTAL:</b>	<b><u>1,496</u></b>
Number of prisoners requiring treatment but not yet receiving treatment		
	<b>TOTAL:</b>	<b><u>2,554</u></b>